Stoke Therapeutics (STOK) Stock News
$STOK · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Stoke Therapeutics (STOK) in the past 30 days. BORSA’s news read on STOK is leaning bullish at 57/100, −1 over 24 hours, based on 1 company event over the past 30 days. Stoke Therapeutics’ next earnings report is scheduled for Tuesday, Nov 3.
The wire on $STOK
newest first · updated · direct subject stories onlyStoke Therapeutics to present STK-002 data at AAO 2026, OSPREY study dosing third cohort by year-end
Stoke Therapeutics (STOK) announced two presentations of STK-002 data at AAO 2026. STK-002 is an investigational RNA-based therapy for autosomal dominant optic atrophy (ADOA), a rare inherited optic nerve disorder with no approved treatments. The Phase 1 OSPREY study has completed dosing in the first two cohorts; the third cohort is expected to complete by year-end 2026. Initial safety and efficacy data from cohorts three and four are anticipated in H1 2027.
neutral 50 · impact 35